組織蛋白去乙醯脢抑制劑市場的競爭分析 是由出版商La Merie在2009年07月所出版的。
這份英文市場調查報告書包含42 價格從美金560起跳。
本報告書內容包括：針對癌症及其他疾病治療的組織蛋白去乙醯脢（HDAC）抑制劑市場競爭動向調查、現在的研發動向、企業別產品線等。內容綱要摘記如下：
癌症治療中的組織蛋白去乙醯脢抑制劑
癌症治療中的次級組織蛋白去乙醯脢抑制劑
多用途組織蛋白去乙醯脢抑制劑
用於癌症治療外的組織蛋白去乙醯脢抑制劑
從事組織蛋白去乙醯脢抑制劑研發工作的企業
- 4SC
- Access Pharmaceuticals
- Arno Therapeutics
- Celleron Therapeutics
- Chroma Therapeutics
- Crystal Genomics
- Curis
- EnVivo Pharmaceuticals
- Ethical Oncology Science
- Exon Hit therapeutics
- Genextra
- GlaxoSmithKline
- Gloucester Pharmaceuticals
- HUYA Bioscience International
- Italfarmaco
- Johnson & Johnson
- Karus Therapeutics
- Menarini
- Merck & Co
- MethylGene
- Novartis
- Pharmacyclics
- Repligen
- S*Bio
- Servier
- Shenzhen Chipscreen Biosciences
- Sigma Tau
- Syndax Pharmaceuticals
- 大鵬藥品
- Topotarget
Abstract
Product description
The present Competitive Intelligence Report about HDAC Inhibitors provides a
competitor evaluation in the field of novel molecular entities inhibiting
histone deacetylase for treatment of cancer and other diseases as of July
2009. Purchase of the downloadable pdf report includes a 6-month online access
to the data of the report and any updates since the publication date.
Credentials to access the database will be sent by e-mail and allow online
work with the project data to print or export an individual report.
Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential
anticancer agents for the treatment of solid and hematological malignancies.
HDAC inhibition causes acetylated nuclear histones to accumulate in both tumor
and normal tissues, providing a surrogate marker for the biological activity
of HDAC inhibitors in vivo. The effects of HDAC inhibitors on gene expression
are highly selective, leading to transcriptional activation of certain genes
such as the cyclin-dependent kinase inhibitor but repression of others. HDAC
inhibition not only results in acetylation of histones but also transcription
factors such as p53, GATA-1 and estrogen receptor-alpha.
HDAC inhibitors are potent antiproliferative agents with relatively little
effect on normal tissues. The first generation of pan-HDAC inhibitor produced
clinical benefit and the first representative of this class is already
marketed for cutaneous T-cell lymphoma. The second generation inhibitors are
rationally designed with improved specificity and are currently in broad
clinical evaluation for a number of different cancer indications, alone and in
combination.
Apart from oncology, HDAC inhibitors are also being evaluated in other
indications, such as Huntington' s disease or Friedreich' s ataxia because
transcriptional dysregulation has been shown to be a major pathology in
Huntington' s Disease. There are CNS-penetrant, orally bioavailable HDAC
inhibitors which are being pursued for use as a cognition enhancing agent in
neurodegenerative diseases such as Alzheimer' s disease. Other indications
under evaluation are fungal infections, psoriasis and inflammatory diseases.
The report includes a compilation of current active projects in research and
development of HDAC inhibitors in oncology and other indications. In addition,
the report lists company-specific R&D pipelines of HDAC inhibitors. Competitor
projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Table of Contents
- Pan-HDAC Inhibitors in Oncology Indications
- Sub-Class Selective HDAC Inhibitors in Oncology
- Multi--Specific HDAC Inhibitors
- HDAC Inhibitors in Non-Oncology Indications
- Corporate HDAC Inhibitor R&D Pipelines
- About La Merie
Corporate HDAC Inhibitor Product and R&D Pipelines
- 4SC
- Access Pharmaceuticals
- Arno Therapeutics
- Celleron Therapeutics
- Chroma Therapeutics
- Crystal Genomics
- Curis
- EnVivo Pharmaceuticals
- Ethical Oncology Science (EOS)
- Exon Hit Therapeutics
- Genextra (DAC)
- GlaxoSmithKline (GSK)
- Gloucester Pharmaceuticals
- HUYA Bioscience International
- Italfarmaco
- Johnson & Johnson (J&J)
- Karus Therapeutics
- Menarini
- Merck & Co
- MethylGene
- Novartis
- Pharmacyclics
- Repligen
- S*Bio
- Servier
- Shenzhen Chipscreen Biosciences
- Sigma Tau
- Syndax Pharmaceuticals
- Taiho Pharmaceutical Co.
- Topotarget
